Biodesix Inc. (BDSX)
0.92
-0.03 (-2.67%)
At close: Feb 20, 2025, 3:59 PM
0.92
0.10%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 0.91 |
| Market Cap | 133.83M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.37 |
| PE Ratio (ttm) | -2.49 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.02 |
| Volume | 103,775 |
| Avg. Volume (20D) | 452,169 |
| Open | 0.95 |
| Previous Close | 0.95 |
| Day's Range | 0.91 - 0.97 |
| 52-Week Range | 0.86 - 2.04 |
| Beta | undefined |
About BDSX
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. ...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 28, 2020
Employees 217
Stock Exchange NASDAQ
Ticker Symbol BDSX
Website https://www.biodesix.com
Analyst Forecast
According to 4 analyst ratings, the average rating for BDSX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 226.09% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Biodesix Inc. is scheduled to release its earnings on Mar 3, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-23.53%
Biodesix shares are trading lower after the compan...
Unlock content with
Pro Subscription
10 months ago
-7.28%
Biodesix shares are trading lower after the company announced pricing of its oversubscribed and upsized underwritten offering of common stock and concurrent private placement.
